Prices delayed by at least 15 minutes | Print
Abliva AB (ABLI)
Open
0.1592 SEK
Previous close
0.1596 SEK
Trade high
0.184 SEK
Volume
2,787,638
Year high
0.32 SEK
Year low
0.14 SEK
Dividend yield
-
Market capitalisation
175.13 mn SEK
P/E ratio
-
ISIN
SE0002575340
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Share price
Company profile
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.